





		EMLc	Codes ATC: J01CR02
Indication	Acute otitis media	Code ICD11: AB00	
INN	Amoxicillin + clavulanic acid		
Type de médicament	Chemical agent		
Groupes d'antibiotiques	A ACCESS		
Type de liste	Liste de base (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection ; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc) ; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc) Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt) (EMLc) ; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) (EMLc) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt) ; 875 mg (as trihydrate) + 125 mg (as potassium salt) (EML)		
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2023 (TRS 1049)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 		
Wikipédia	Amoxicillin + clavulanic acid 		
DrugBank	Amoxicillin  , Clavulanic acid (Clavulanate) 		

Recommandation du comité d'experts

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.

Recommandations de la LME : Acute otitis media

Premier choix

Second choix

amoxicillin

amoxicillin + clavulanic acid

